STAR - Development of a Novel Addiction Medicine Therapeutic - Assessing Whether Semaglutide Reduces Alcohol Craving

The STAR study (Semaglutide Therapy for Alcohol Reduction) represents a translational research effort examining whether semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for diabetes and weight-loss, can reduce alcohol craving and symptoms of Alcohol Use Disorder (AUD). This work builds on converging lines of evidence from preclinical models and clinical observations: animal studies in rodents and nonhuman primates have shown marked reductions in drug and alcohol consumption following GLP-1–based treatments, and clinicians have observed that some patients prescribed semaglutide for diabetes or weight loss report decreased urges to drink. A recently published human case series in The Journal of Clinical Psychiatry reported that six patients receiving semaglutide for weight-loss pharmacotherapy experienced significant decreases in their Alcohol Use Disorders Identification Test (AUDIT) scores, offering the first human evidence that semaglutide may specifically reduce AUD symptoms. The STAR clinical trial, conducted in Tulsa at the OSU Hardesty Center for Clinical Research and Neuroscience, is a randomized, placebo-controlled effort designed to move beyond case series and determine definitively whether semaglutide is safe and effective as a therapeutic for AUD. Funded by the Hardesty Family Foundation and the OSU Center for Health Sciences, STAR exemplifies collaborative research between institutions: investigators at the OU-TU School of Community Medicine and Oklahoma State University Center for Health Sciences have combined clinical and basic science expertise to pursue this novel therapeutic application.

A sister study in Baltimore funded by the National Institute on Drug Abuse is underway, reflecting wider interest in GLP-1-based approaches to addiction. Investigators emphasize that the initial case-series findings are preliminary and that larger, rigorously controlled trials are needed to validate and extend these results. Until placebo-controlled trial outcomes are available, clinicians are advised to continue recommending established behavioral treatments and FDA-approved medications for AUD. Nonetheless, STAR could expand the therapeutic arsenal against alcohol use disorder by repurposing a medication with an established safety profile for metabolic indications. The trial's design, situated in an academic clinical research environment, aims to assess both reductions in alcohol craving and broader changes in AUD symptomatology, using validated measures such as AUDIT scores. If STAR demonstrates clinically meaningful benefits, it would support further development of GLP-1 receptor agonists for addiction medicine, inform mechanisms linking metabolic and reward pathways, and potentially improve outcomes for individuals struggling with AUD. The study thus serves both as a test of a specific therapeutic hypothesis and as a model for interdisciplinary collaboration in advancing novel interventions for substance use disorders.